VJHemOnc

At #SOHO2025, we caught up with Valeria Santini, who provided an overview of recent advances in the treatment of lower-risk MDS, with a focus on therapies for anemia.🩸

Click here to watch the interview:

👉 buff.ly/OBaMhs6 👈

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:

👉 buff.ly/rBWUBYh 👈

#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky

In an interview from #IMS25, Bruno Paiva shares insights into MRD dynamics and early immunotherapy interception in #MultipleMyeloma.🩸

Watch here:

👉 buff.ly/pzzJrRm 👈

#mmMRD #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

#iwAL25 | Charlie Craddock answers YOUR transplantation questions in a special Ask the Expert session!

Watch here:

👉 buff.ly/TRqoc4q%F0%9...

#HemOnc #ImmunoOnc #AMLsm #BMTsm #Leusm #BloodSky #HemeSky #MedSky

We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.

Click here to check out the interview:

🎥 buff.ly/20uHc4O

#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky

Gray zone lymphoma is a rare subtype of #NonHodgkinLymphoma. 🩸

Learn more about this entity from Kieron Dunleavy:

👉 buff.ly/VPFTEid 👈

#LYMsm #Lymphoma #HemOnc #SOHO2025 #BloodSky #HemeSky #MedSky

#IMS25 | Meera Mohan of @medicalcollegeofwi.bsky.social discusses a study investigating outcomes after a limited duration of bispecific antibody therapy in patients with R/R #MultipleMyeloma:

🎥 buff.ly/I3wa6uz

#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky @myeloma-society.bsky.social

🎥 Sanam Loghavi and Guillermo Montalban-Bravo of @mdanderson.bsky.social sat down at #iwAL25 to share insights into the diagnosis and classification of CMML, commenting on how the current approach to this could be refined:

👉 buff.ly/5ZwQxnP 👈

#Leusm #HemOnc #RareDisease #MDSsm #BloodSky #HemeSky

Thank you to Claudio Cerchione for stopping by at #IMS25 to share insight into the use of anti-CD38–based quadruplet regimens for patients with transplant-ineligible #MultipleMyeloma.🩸

Check out the interview here:

👉 buff.ly/jVocJUD 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

We recently spoke with Pankit Vachhani, who discussed the potential of MDM2 inhibitors for treating MPNs, outlining the encouraging results observed to date with the MDM2 inhibitor navtemadlin.

Click here to watch:

🎥 buff.ly/cBf3tFe

#MPNsm #HemOnc #BloodSky #HemeSky #MedSky

PNH is a rare acquired clonal hematopoietic stem cell disorder.🩸

Learn about the biology, diagnosis, & treatment of this non-malignant disease in our new article, featuring interviews with leading experts Austin Kulasekararaj, Catherine Flynn, & Jens Panse!

Click here:
🔗 buff.ly/WRSulMR

#MedSky

Want to learn about the potential value of circulating tumor DNA in Hodgkin #lymphoma? 🧬🩸

Make sure to watch our recent interview with Jonathan Friedberg of @wilmotcancer.bsky.social here:

🎥 👉 buff.ly/fZ3K2nD

#HodgkinLymphoma #LYMsm #HemOnc #SOHO2025 #BloodSky #HemeSky #MedSky

At #iwAL25, leading experts Mark Levis, Eunice Wang, and Sanam Loghavi participated in a thought-provoking debate about the value and utility of MRD in the management of adults with newly diagnosed AML.🩸

Watch it here: 👉 buff.ly/XfMfsmQ

#AMLsm #Leusm #MRD #HemOnc #BloodSky #HemeSky #MedSky

At #SOHO2025, Sarah Tasian shared insights into the management of Ph-like ALL, highlighting the move toward an individualized, precision medicine approach.

Watch the interview here:

👉 buff.ly/E837gwk 👈

#ALLsm #Leusm #Leukemia #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc

In an interview from #SOHO2025, Matteo Della Porta shares insights into the significance of anemia in MDS & MPNs, highlighting the need to develop effective therapies for this clinical feature.

Click to watch:

👉 buff.ly/rXyC3pf 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

It's always a pleasure to catch up with Hermann Einsele!😊

At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸

Click here to watch the interview:

👉 buff.ly/Bc1gG2R 👈

#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

How can clinicians identify patients with MPNs whose disease is in the accelerated or blast phase? 🩸

🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:

👉 buff.ly/ygLFHa4 👈

#MPNsm #HemOnc #MedSky #HemeSky #BloodSky

🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

At #IMS25, we spoke with Gareth Morgan, who provided practical advice to support earlier recognition and diagnosis of #amyloidosis.🩸

Click here to watch:

👉 buff.ly/iPaNSjm 👈

@myeloma-society.bsky.social #HemOnc #BloodSky #HemeSky #MedSky

Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸

Watch our interview with Britten Gordon from #iwCLL2025:

🎥 buff.ly/eKQamE2

#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky

At #IMS25, we caught up with Xavier Leleu of to hear about the Phase III IRAKLIA trial investigating isatuximab administered subcutaneously via an on-body injector versus intravenously in patients with R/R #MultipleMyeloma:

🎥 buff.ly/T67u8VR

#MMsm #Myeloma #TrialUpdate @myeloma-society.bsky.social

🎥 Ranjit Nair of @mdanderson.bsky.social shares the promising results of a Phase I study evaluating surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with R/R #NonHodgkinLymphoma:

🎥 👉 buff.ly/k5zLkkg

#SOHO2025 #LYMsm #Lymphoma #CTSM @societyofhemonc.bsky.social

Want to hear the evidence supporting the use of MRD-guided treatment in #MultipleMyeloma? 🤔🩸

Check out our interview from #IMS25 with Noemi Puig:

🎥 buff.ly/CtaSWCC

#MMsm #Myeloma #mmMRD #HemOnc @myeloma-society.bsky.social

In an interesting interview from #SOHO2025, David Swoboda discusses the development of a novel AI-driven virtual tumor board designed to improve diagnosis, prognosis, and treatment recommendations in MDS.

Watch here:

🎥 buff.ly/wrh0OvA

#MDSsm #HemOnc #AI #BloodSky #HemeSky #MedSky

Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸

Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:

🎥 buff.ly/AnTQebz

#CARTCell #ImmunoOnc #CLLsm #Leusm

Missed out on #iwCLL2025?🩸

Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:

👉 buff.ly/GBOkgBn 👈

#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc

In an interview from #SOHO2025, Gloria Iacoboni shares insights into the importance of bridging & holding therapy in patients with aggressive B-cell #lymphoma, highlighting the need to differentiate between the two terms:

👉 buff.ly/PlcXlRs 👈

#LYMsm #CARTCell #ImmunOnc #HemOnc #BloodSky #HemeSky

As part of #BloodCancerAwarenessMonth, we're bringing you a special podcast series!

Our most recent episode features @rahulbanerjeemd.bsky.social, who shares expert insights into the definition & complexities of financial & time toxicity in #myeloma.

🎧 buff.ly/GNUBCFz

#MMsm #BMTsm #HemOnc

🎥 @mhairicopland.bsky.social of @uofglasgow.bsky.social comments on the challenges of co-targeting in CML, highlighting the need to balance efficacy with minimizing additional side effects, particularly in patients who have achieved remission:

👉 buff.ly/eSCKsvx 👈

#SOHO2025 #CMLsm #Leusm #HemOnc